On June 25, 2025, Aligos Therapeutics, Inc. held its Annual Meeting where stockholders approved an amendment to increase shares reserved under the 2020 Plan by 1,000,000 shares and authorized voting common stock from 20 million to 100 million. Additionally, non-voting common stock was increased from 800,000 to 15.8 million shares.